Why the study?
Does bezafibrate prevent or delay the onset of type 2 diabetes in patients with coronary artery disease and impaired fasting glucose?
Population
303 nondiabetic patients 42 to 74 years of age with coronary artery disease and impaired fasting glucose.
Comparison
Bezafibrate retard 400 mg once a day vs Placebo once a day
Design
RCT, placebo-controlled
Follow-up
6.2 years
Authors
Loading...
Bezafibrate may warrant consideration for diabetes prevention in CAD with impaired fasting glucose; extends fibrate evidence to glycemic outcomes in this RCT.
Does bezafibrate prevent or delay the onset of type 2 diabetes in patients with coronary artery disease and impaired fasting glucose?
Bezafibrate significantly reduces the incidence and delays the onset of type 2 diabetes in patients with coronary artery disease and impaired fasting glucose.
Tenenbaum et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: